



Four outstanding leaders in the pharmaceutical industry and biotechnology sector join the THERAVECTYS Board of Directors.

A spin-off from the Pasteur Institute, THERAVECTYS is developing a new generation of vaccines, with a therapeutic vaccine against HIV as the initial application

Four internationally recognized leaders join the THERAVECTYS Board of Directors to bring their expertise of the pharmaceutical industry and biotechnology sector plus their experience in industrial partnerships to the company.

Paris, July 4, 2012

THERAVECTYS announced the appointment of four new directors, Pierre LEPIENNE, former Executive Vice President of Synthélabo and later Sanofi-Synthélabo, Tom McKILLOP, former CEO of Astra Zeneca, Jean STEPHENNE, former CEO of GSK Bio, the vaccine division of GlaxoSmith-Kline, and Judith GRECIET, CEO of BioAlliance Pharma. These four individuals will help lead the company in its international development and clinical trial phases up through the marketing of its vaccine candidates.

THERAVECTYS, a French biotechnology company, is developing a new generation of vaccines based on lentiviral vector technology. The result of fundamental research conducted at the Pasteur Institute, this breakthrough technology is expected to enable preventing or effectively treating many diseases in which the induction of effective cellular immune response is required: viral diseases (HIV), bacterial or parasitic diseases, cancers...

#### An innovative vaccine approach for HIV-positive patients

Since its creation, THERAVECTYS has been working on the development of a therapeutic vaccine against HIV. This vaccine, for which the Phase I/II clinical trials are scheduled for the second half of 2012, should allow HIV-positive patients under combination therapy to stop antiretroviral treatment long-term and perhaps even permanently once vaccinated. Backed by an exclusive global licensing agreement with the Pasteur Institute, THERAVECTYS continues its research and development work on new applications. Alone, or in collaboration with other pharmaceutical companies, THERAVECTYS aims to lead the future development of new vaccine candidates.

#### Towards industrial partnerships

"The arrival of these four directors marks a new stage in the company's development. Their backgrounds, experience, and industry knowledge will enable the company to accelerate the formation of industrial partnerships," said Renaud VAILLANT, CEO of THERAVECTYS.

Pierre LEPIENNE (Director) is one of the founders of the Synthélabo pharmaceutical group, where he served as

Executive Vice President and a member of the Board of Directors. Upon the merger of Sanofi and Synthélabo, he became Executive Vice President, Secretary, and a member of the Board of Directors of the group.

Tom McKILLOP (Independent Director) Ph.D. in chemistry. In 1975, Tom McKillop joined the ICI Pharmaceuticals Group which became the Zeneca laboratory in 1994 when he took over as CEO. Following a successful merger with the Swedish laboratory Astra in 1999, he stayed on as the Group's CEO until 2006.

Judith GRECIET (Independent Director) Ph.D. in pharmacy with an emphasis on management and pharmaceutical marketing. After a successful career with Wyeth Pharmaceuticals France (now Pfizer), LFB, Zeneca, and Pharmacia, Judith joined Eisai France in 2007 where she was the President for three years. In 2011, she joined the BioAlliance Pharma company (EPA: BIO) where she was appointed CEO in May 2011.

Jean STEPHENNE (Independent Director) has served as CEO of GSK Bio, the vaccine division of the GlaxoSmithKline group, since 1991. An agronomist specializing in chemistry and bio-industry, he joined SmithKline in 1974 where he went on to become Director of vaccine production and then Director of Research and Development.

### Towards anti-HIV clinical trials

“THERAVECTYS should be the first company in the world to initiate a clinical trial of an anti-HIV therapeutic vaccination with lentiviral vectors,” said Jean STEPHENNE, who continued, «I am very happy to bring my knowledge of the pharmaceutical industry, and particularly the vaccine sector, and thus contribute to THERAVECTYS' international development.»

These four individuals coming on board complements THERAVECTYS' Board of Directors, chaired by Jean-Pierre KINET, co-founder of AB Science (Euronext: AB), and includes the Pasteur Institute represented by Jean DEREGNAUCOURT, Director of Research Applications and Industrial Relations, John PIETERS, former CEO of Amgen France, iXLife, a longstanding investor in the company represented by Albert HSIA and Renaud VAILLANT, CEO of THERAVECTYS.

## About THERAVECTYS

THERAVECTYS, a French biotechnology company, has developed a new generation of vaccines based on lentiviral vector technology.

The result of fundamental research conducted at the Pasteur Institute, this breakthrough technology is expected to enable preventing or effectively treating many diseases in which the induction of effective cellular immune response is required: viral diseases (HIV), bacterial or parasitic diseases, cancers... Since its creation, THERAVECTYS has been working on the development of a therapeutic vaccine against HIV. This vaccine,

for which the Phase I/II clinical trial is scheduled for the second half of 2012, should allow HIV-positive patients under combination therapy to stop antiretroviral treatment long-term and perhaps even permanently once vaccinated. Backed by an exclusive global licensing agreement with the Pasteur Institute, THERAVECTYS continues its research and development work on new applications.

Alone, or in collaboration with other pharmaceutical companies, THERAVECTYS aims to lead the future development of new vaccine candidates.

### For more information:

+33 1 43 90 19 20 - [contact@theravectys.com](mailto:contact@theravectys.com)

